
In Psoriasis, IL-23 Inhibitors Tied to Lower PsA Risk Than JAKs
Key Takeaways
- TriNetX target trial emulation matched psoriasis patients without baseline PsA to compare incident PsA after starting JAK inhibitors versus IL-23 inhibitors or versus IL-17 inhibitors.
- Relative to IL-23 inhibitors, JAK initiators had higher PsA risk (HR 1.32; 95% CI, 1.20-1.46) and higher cumulative incidence (19.0% vs 15.1%).
IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.
Patients with psoriasis who started an IL-23 inhibitor were less likely to develop psoriatic arthritis (PsA) during up to 5 years of follow-up than those who started a Janus kinase (JAK) inhibitor. Those who started an IL-17 inhibitor were more likely to develop it than JAK inhibitor users, according to a retrospective study published in the Journal of Drugs in Dermatology.1
PsA affects up to 30% of patients with psoriasis and is a major long-term complication of the disease. Both conditions are driven by dysregulated immune signaling along the IL-23/IL-17 axis. IL-17 and IL-23 inhibitors are now cornerstone therapies for moderate to severe psoriasis. JAK inhibitors, also widely used for inflammatory joint disease, are another systemic option, typically reserved for patients who do not respond to or tolerate conventional disease-modifying antirheumatic drugs. Whether these classes differ in their effect on PsA risk has been unclear. The authors noted that head-to-head prevention trials across biologic and small-molecule classes are unlikely to be conducted.
How Does Psoriatic Arthritis Risk Compare With IL-23, IL-17, and JAK Inhibitors?
Researchers from SUNY Downstate Health Sciences University and the VA New York Harbor Healthcare System used the TriNetX federated research network and a target trial emulation design. They ran 2 propensity score–matched comparisons of adults with psoriasis and no prior PsA. JAK inhibitor initiators were matched 1:1 with IL-23 inhibitor initiators (n = 5027 per group) and, separately, with IL-17 inhibitor initiators (n = 5300 per group). The matching accounted for demographics, comorbidities, psoriasis subtype, baseline joint pain and other musculoskeletal symptoms, prior medication use, and health care utilization.
During up to 5 years of follow-up, JAK inhibitor initiators had a higher hazard of PsA than IL-23 inhibitor initiators (hazard ratio [HR], 1.32; 95% CI, 1.20-1.46) but a lower hazard than IL-17 inhibitor initiators (HR, 0.66; 95% CI, 0.61-0.72; log-rank P < .001 for both). Cumulative incidence was 15.1% with IL-23 inhibitors vs 19.0% with JAK inhibitors in the first comparison, and 27.1% with IL-17 inhibitors vs 16.8% with JAK inhibitors in the second. Negative control outcomes, such as presbyopia and ingrown nails, showed no between-group differences, a check intended to detect residual confounding.
What Are the Study's Limitations, and What Did Prior Research Find?
The authors noted several limitations. PsA was identified by International Classification of Diseases, Tenth Revision codes, which may introduce misclassification. Established PsA predictors, including psoriasis severity, disease duration, nail involvement, and family history, were not measurable in the data set, which the authors said may contribute to residual confounding. IL-23 and IL-17 inhibitors were each compared with a separate JAK inhibitor cohort rather than with each other. The mean follow-up for JAK inhibitor users vs comparators was 888 vs 925 days in the IL-23 analysis and 850 vs 1017 days in the IL-17 analysis.1
In earlier research, a 2023 retrospective cohort study, also drawn from TriNetX, examined 15,501 adults with psoriasis who were newly prescribed a biologic between 2014 and 2022.² Overall, 976 patients (6.3%) developed inflammatory arthritis, or 2.6 cases per 100 person-years. Compared with those receiving tumor necrosis factor (TNF) inhibitors, patients receiving IL-12/23 inhibitors (adjusted HR, 0.58; 95% CI, 0.43-0.76) or IL-23 inhibitors (adjusted HR, 0.41; 95% CI, 0.17-0.95) had a significantly lower risk, while risk with IL-17 inhibitors did not differ significantly (adjusted HR, 0.86; 95% CI, 0.54-1.38). The IL-23 inhibitor finding held in 3 of 6 sensitivity analyses, and the investigators noted that prospective studies are needed to confirm the results.2
References
- Adler R, Kozlov M, Sash S, et al. Progression to psoriatic arthritis among psoriasis patients treated with JAK inhibitors compared with IL-17/23 inhibitors. J Drugs Dermatol. 2026;25(11):997-1002. doi:10.36849/JDD.9963
- Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200-e207. doi:10.1016/S2665-9913(23)00034-6
Related to this article








